Advertisement

Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib

Emily M. McWilliams, Christopher R. Lucas, Timothy Chen, Bonnie K. Harrington, Ronni Wasmuth, Amanda Campbell, Kerry A. Rogers, Carolyn M. Cheney, Xiaokui Mo, Leslie A. Andritsos, Farrukh T. Awan, Jennifer Woyach, William E. Carson III, Jonathan Butchar, Susheela Tridandapani, Erin Hertlein, Carlos E. Castro, Natarajan Muthusamy and John C. Byrd

Article Information

Citation 
vol. 3 no. 3 447-460
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted September 4, 2018
  • Accepted January 2, 2019
  • Published online February 8, 2019.


Contributors 
  • Emily M. McWilliams, 1Biomedical Sciences Graduate Program, College of Medicine,2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Christopher R. Lucas, 3Department of Mechanical and Aerospace Engineering, College of Engineering,
  • Timothy Chen, 1Biomedical Sciences Graduate Program, College of Medicine,2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Bonnie K. Harrington, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,4Department of Veterinary Biosciences, College of Veterinary and Comparative Medicine,
  • Ronni Wasmuth, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Amanda Campbell, 1Biomedical Sciences Graduate Program, College of Medicine,
  • Kerry A. Rogers, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Carolyn M. Cheney, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Xiaokui Mo, 5Center for Biostatistics,
  • Leslie A. Andritsos, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Farrukh T. Awan, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Jennifer Woyach, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • William E. Carson III, 6Division of Surgical Oncology, Department of Surgery, College of Medicine and OSU Comprehensive Cancer Center, and
  • Jonathan Butchar, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Susheela Tridandapani, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Erin Hertlein, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • Carlos E. Castro, 3Department of Mechanical and Aerospace Engineering, College of Engineering,
  • Natarajan Muthusamy, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,
  • John C. Byrd, 2Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center,7Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output